2025.10.27
PARAMUS, NJ, UNITED STATES, October 27, 2025 /EINPresswire.com/ -- Forest Hills Lab (“FHL”), an innovative global life sciences company focused on regenerative medicine and medical aesthetics, announces the appointment of Lisa L. Bollinger, M.D. as Chief Medical Officer, effective October 16, 2025. With over 30 years of experience in pediatric drug development and regulatory affairs, Dr. Bollinger is a highly accomplished pediatrician with a proven track record of success working within the U.S. FDA and in leading biotechnology and pharmaceutical companies.
Prior to joining FHL, Dr. Bollinger founded Bollinger Regulatory Consulting (BRC), providing regulatory and clinical expertise to venture capital firms. Previously, she served as Vice President, Regulatory Affairs, Global Regulatory Affairs and Clinical Safety (GRACS) at Merck & Co., leading a team in general medicine, and for nearly 10 years held senior roles at Amgen Inc., primarily focusing on global regulatory affairs and safety, with a particular focus on pediatrics.
At the FDA, Dr. Bollinger held leadership roles for over 12 years, including Associate Director at the Office of New Drugs at the Center for Drug Evaluation and Research (CDER), where she oversaw the Pediatric and Maternal Health Staff (PMHS) and served as the Chair of the Pediatric Review Committee. Prior to the FDA, Dr. Bollinger served as a staff pediatrician at several hospitals within the National Health Service Corps, United States Public Health Service. She also served as an Adjunct Professor of Pediatrics at the Uniformed Services University of the Health Sciences. “I am thrilled to join the exceptional team at FHL. I look forward to collaborating with the team to help accelerate FHL’s pipeline and clinical development,” said Dr. Bollinger. “With her extensive experience across life sciences and regulatory operations, coupled with her background as a practicing pediatrician, Lisa brings an impressive skill set to our leadership team,” said Alex Yang, Chair and Chief Executive Officer at FHL. “As we continue to advance our pipeline, her proven track record in leading the development of novel therapies will provide critical insights as we progress to potential future approvals.”
Dr. Bollinger holds a Doctor of Medicine (M.D.) degree from the Uniformed Services University of the Health Sciences and completed her residency in pediatrics at the University of California, Davis Medical Center. Dr. Bollinger is the author of numerous peer-reviewed publications and currently serves on the Board of Directors at Apogee Therapeutics (Nasdaq: APGE).
About Forest Hills Lab Forest Hills Lab is an innovative global life sciences company focused on regeneration and committed to improving well-being in our rapidly aging society. The therapeutics division of Forest Hills Lab is a clinical stage biopharmaceutical platform with seven potentially disease-modifying therapies for neurological conditions. Our candidates have demonstrated promising outcomes in addressing various neurodegenerative disease pathways. Our lead pipeline candidates include FHL-101, which has recently completed a Phase 1 clinical trial, and FHL-301, which is preparing to enter a Phase 2 clinical trial in Parkinson’s disease. Our platform seeks partners to add candidates to our pipeline towards clinical-stage development, collaborating on its co-development and licensing-out possibilities. For more information, please visit fhltherapeutics.com and foresthillslab.com.
About Mstone Partners Forest Hills Lab’s largest shareholder is Mstone Partners, an incubator of biotech, healthcare and AI companies. Mstone founds, staffs, develops, and grows portfolio companies by building upon novel technology as well as human and investment capital. Mstone has also established several companies under its platform, managing a portfolio of drug development companies in a centralized, hub-and-spoke model.
